Colin Carrie on Questions Passed as Orders for Returns

With regard to the Public Health Agency of Canada (PHAC) and Health Canada (HC): (a) did PHAC or HC receive or become aware of documents related to Pfizer-BioNTech which were the subject of a court order requiring their release to the public starting around January 6, 2022; (b) if the answer to (a) is affirmative, (i) when did the government receive them, (ii) which department or agency reviewed them, (iii) what conclusions and recommendations were arrived at, (iv) was a risk versus benefit analysis conducted after the review, and, if so, what were the findings, (v) when did the review commence and finish; (c) did PHAC or HC receive or become aware of the document titled: “5.3.6 CUMULATIVE ANALYSIS OF POST-AUTHORIZATION ADVERSE EVENT REPORTS OF PF-07302048 (BNT162B2) RECEIVED THROUGH 28-FEB-2021”, and, if so, (i) on what date did PHAC or HC review the document, (ii) what were the conclusions and recommendations that resulted from the review of the document, (iii) when did the review commence and finish, (iv) which Canadian federal health agency was assigned to review this document and when; (d) what are PHAC’s and HC’s latest warnings or instructions to health care professionals who advise Canadians about the Pfizer-BioNTech COVID-19 vaccine; (e) do the warnings or instructions in (d) consider the adverse events of special interest identified in the Pfizer study; and (f) will the government notify Canadians about the events in (d)?